[1] FREDDIE B,JACQUES F,ISABELLE S,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3] SIMPSON P T,REIS-FILHO J S,LAKHANI S R.Breast pathology:beyond morphology[J].Semin Diagn Pathol,2010,27(1):91-96.
[4] MARUSYK A,ALMENDRO V,POLYAK K.Intra-tumour heterogeneity:a looking glass for cancer?[J].Nat Rev Cancer,2012,12(5):323-334.
[5] GERDES J,SCHWAB U,LEMKE H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Cancer,1983,31(1):13-20.
[6] GERDES J.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonalantibody Ki-67[J].Am J Pathol,1991,138(4):867-873.
[7] XIANG Q M,WANG L W,YUAN J P,et al.Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer[J].Exp Mol Pathol,2015,99(1):133-138.
[8] LI L T,JIANG G,CHEN Q,et al.Ki67 is a promising molecular target in the diagnosis of cancer (review)[J].Mol Med Rep,2015,11(3):1566-1572.
[9] DENKERT C,BUDCZIES J,VON MINCKWITZ G,et al.Strategies for developing Ki67 as a useful biomarker in breast cancer[J].Breast,2015,24(Suppl 2):S67-S72.
[10] STUART-HARRIS R,CALDAS C,PINDER S E,et al.Proliferation markers and survival in early breast cancer:a systematic review and meta-analysis of 85 studies in 32825 patients[J].Breast,2008,17(4):323-334.
[11] CHEANG M C,CHIA S K,VODUC D,et al.Ki67 index,HER2 status,and prognosis of patients with luminal B breast cancer[J].J Natl Cancer Inst,2009,101(10):736-750.
[12] GOLDHIRSCH A,WOOD W C,COATES A S,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Galleninternational expert consensus on the primary therapy of early breast cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
[13] ZURRIDA S,BAGNARDI V,CURIGLIANO G,et al.High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy[J].Eur J Cancer,2013,49(15):3083-3092.
[14] GALLI G,BREGNI G,MENEGHINI E,et al.F02*Ki67,tumor stage (TS) and axillary node metastases (ANMs):a complex relationship[J].Ann Oncol,2016,27(Suppl4):iv59-iv59.
[15] FASCHING P A,HEUSINGER K,HAEBERLE L,et al.Ki67,chemotherapy response,and prognosis in breast cancer patients receiving neoadjuvant treatment[J].BMC Cancer,2011,11:486.
[16] CABRERA-GALEANA P,MUNOZ-MONTANO W,LARA-MEDINA F,et al.Ki67 changes identify worse outcomes in residual breast cancer tumors after neoadjuvantchemotherapy[J].Oncologist,2018,23(6):670-678.
[17] MEDEIROS L R,DUARTE C S,ROSA D D,et al.Accuracy of magnetic resonance in suspicious breast lesions:a systematic quantitative review and meta-analysis[J].Breast Cancer Res Treat,2011,126(2):273-285.
[18] LEITHNER D,WENGERT G J,HELBICH T H,et al.Clinical role of breast MRI now and going forward[J].Clin Radiol,2018,73(8):700-714.
[19] HAYES C,PADHANI A R,LEACH M O.Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging[J].NMR Biomed,2002,15(2):154-163.
[20] BICKEL H,PINKER-DOMENIG K,BOGNER W,et al.Quantitative apparent diffusion coefficient as a noninvasive imaging biomarker for the differentiation of invasive breast cancer and ductal carcinoma in situ[J].Invest Radiol,2015,50(2):95-100.
[21] THAKUR S B,DURANDO M,MILANS S,et al.Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI:A potential predictor for an oncotype Dx test recurrence score[J].J Magn Reson Imaging,2018,47(2):401-409.
[22] ARCHER C D,PARTON M,SMITH I E,et al.Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer[J].Br J Cancer,2003,89(6):1035-1041.
[23] PICKLES M D,GIBBS P,LOWRY M,et al.Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer[J].Magn Reson Imaging,2006,24(7):843-847.
[24] PARK S H,MOON W K,CHO N,et al.Diffusion-weighted MR imaging:pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer[J].Radiology,2010,257(1):56-63.
[25] JENSEN L R,GARZON B,HELDAHL M G,et al.Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients[J].J Magn Reson Imaging,2011,34(5):1099-1109.
[26] FANGBERGET A,NILSEN L B,HOLE K H,et al.Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging[J].Eur Radiol,2011,21(6):1188-1199.
[27] RICHARD R,THOMASSIN I,CHAPELLIER M,et al.Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer[J].Eur Radiol,2013,23(9):2420-2431.
[28] NILSEN L,FANGBERGET A,GEIER O,et al.Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy[J].Acta Oncol,2010,49(3):354-360.
[29] WOODHAMS R,KAKITA S,HATA H,et al.Identification of residual breast carcinoma following neoadjuvant chemotherapy:diffusion-weighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings[J].Radiology,2010,254(2):357-366.
[30] 王铮,苏丹柯,赖少侣,等.直肠癌磁共振扩散加权成像ADC值与Ki-67表达水平的相关性[J].实用放射学杂志,2016,32(4):551-553,557.
[31] 周国兴,汪波,郝楠馨,等.膀胱癌表观扩散系数值与PCNA、Ki67表达的相关性研究[J].实用放射学杂志,2013,29(6):947-949,953.
[32] 陆志华,姚鸿欢,周晓伟,等.磁共振扩散加权成像的表观扩散系数与胃癌Ki-67表达及分化程度的关系[J].中华胃肠外科杂志,2016,19(2):204-208.
[33] YANG W,QIANG J W,TIAN H P,et al.Minimum apparent diffusion coefficient for predicting lymphovascular invasion in invasive cervical cancer[J].J Magn Reson Imaging,2017,45(6):1771-1779.
[34] SHEN L,ZHOU G,TONG T,et al.ADC at 3.0T as a noninvasive biomarker for preoperative prediction of Ki67 expression in invasive ductal carcinoma of breast[J].Clin Imaging,2018,52:16-22.
[35] 罗宁斌,苏丹柯,黄向阳,等.乳腺癌新辅助化疗前后MR扩散加权成像ADC值与Ki-67表达水平的相关性研究[J].临床放射学杂志,2018,37(6):922-925.
[36] MATSUOKA A,MINATO M,HARADA M,et al.Comparison of 3.0-and 1.5-tesla diffusion-weighted imaging in the visibility of breast cancer[J].Radiat Med,2008,26(1):15-20.
[37] SUO S,CHENG F,CAO M,et al.Multiparametric diffusion-weighted imaging in breast lesions:Association with pathologic diagnosis and prognostic factors[J].J Magn Reson Imaging,2017,46(3):740-750.
[38] 谢宗玉,程流泉,杨镇.乳腺浸润性导管癌磁共振扩散加权成像表观扩散系数与预后因子表达的关联性分析[J].中国医学影像学杂志,2015,35(3):183-187.
[39] 王记红,张艳.乳腺癌粗针穿刺与术后活检标本病理分级及免疫组化的比较研究[J].中国继续医学教育,2016,8(21):42-44. |
